AVBP
Source profileArriVent BioPharma
Oncology medicines
Company profile
CIK1944885
ExchangeNASDAQ
SectorHealthcare
Tracked assets1
Pipeline assets
Furmonertinib
EGFR-mutant NSCLC
Phase 3Clinical Trial Completion
Upcoming and past catalysts
| Company | Catalyst | Asset | Phase | Expected | Confidence | Status |
|---|---|---|---|---|---|---|
| AVBP ArriVent BioPharma | ClinicalTrials.gov primary completion watch Clinical Trial Completion | Furmonertinib | Phase 3 | December 2026 | month | active |
SEC filings
No sample filings for this company.
Press releases
No sample press releases for this company.